Treatment with the selective COX-2 inhibitor celecoxib ameliorated T2DM-related NASH as shown by anti-inflammatory activity and restraining insulin resistance, probably via suppression of the non-canonical Wnt5a/JNK1 signaling pathway and NF-κB. Here, WNT5A is linked to metabolic dysfunction-associated steatohepatitis.